Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus and Pre-diabetes and Heart Failure (SUGAR-DM-HF)

Trial Profile

Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus and Pre-diabetes and Heart Failure (SUGAR-DM-HF)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Heart failure; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms SUGAR-DM-HF
  • Most Recent Events

    • 28 Aug 2023 Primary endpoint (Left Ventricular End Systolic Volume Index (LVESVI)) has not been met according to Results presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
    • 28 Aug 2023 Results assessing the effect of empagliflozin on CMR-PCWP and the relationship between CMR-PWCP and the remodelling effect of empagliflozin presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
    • 10 Aug 2020 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top